Author: von Buttlar, Xinyu; Reuss, Joshua E.; Liu, Stephen V.; Kim, Chul
Title: EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report Cord-id: 9x52mt73 Document date: 2021_4_28
ID: 9x52mt73
Snippet: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the preferred frontline therapy for EGFR-mutant advanced NSCLC. However, despite its high initial response rates, multiple EGFR-independent mechanisms of resistance have been reported in patients receiving osimertinib. One such mechanism is the emergence of acquired, targetable oncogenic fusion events. It has been documented in other case reports that combination therapies can be efficacious in these scenarios. In our case report
Document: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the preferred frontline therapy for EGFR-mutant advanced NSCLC. However, despite its high initial response rates, multiple EGFR-independent mechanisms of resistance have been reported in patients receiving osimertinib. One such mechanism is the emergence of acquired, targetable oncogenic fusion events. It has been documented in other case reports that combination therapies can be efficacious in these scenarios. In our case report, we present a patient with EGFR-mutant advanced NSCLC who developed an acquired EML4-ALK rearrangement mediating resistance to osimertinib, which was overcome by using a combination of osimertinib with the ALK tyrosine kinase inhibitor alectinib.
Search related documents:
Co phrase search for related documents- acute hypoxia and magnetic resonance: 1, 2, 3
- admission time and magnetic resonance: 1, 2, 3, 4
- adrenal gland lesion and magnetic resonance: 1
Co phrase search for related documents, hyperlinks ordered by date